# Emiel J. Rutgers

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/emiel-j-rutgers/

## Facts

| Field | Value |
| --- | --- |
| Citations | 45,802 |
| Field | Breast Cancer Treatment Studies |
| h-index | 95 |
| i10-index | 370 |
| Last Known Institution | The Netherlands Cancer Institute |
| OpenAlex ID | https://openalex.org/A5014415091 |
| ORCID iD | https://orcid.org/0000-0002-4244-0106 |
| Works | 751 |

## Researcher papers

- [Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013](https://scholariq.org/papers/personalizing-the-treatment-of-women-with-early-breast-cancer-highlights-of-the/)
- [70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer](https://scholariq.org/papers/70-gene-signature-as-an-aid-to-treatment-decisions-in-early-stage-breast-cancer/)
- [De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017](https://scholariq.org/papers/de-escalating-and-escalating-treatments-for-early-stage-breast-cancer-the-st/)
- [Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials](https://scholariq.org/papers/long-term-outcomes-for-neoadjuvant-versus-adjuvant-chemotherapy-in-early-breast/)
- [Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants](https://scholariq.org/papers/prediction-of-breast-cancer-risk-based-on-profiling-with-common-genetic-variants/)
- [Marking Axillary Lymph Nodes With Radioactive Iodine Seeds for Axillary Staging After Neoadjuvant Systemic Treatment in Breast Cancer Patients](https://scholariq.org/papers/marking-axillary-lymph-nodes-with-radioactive-iodine-seeds-for-axillary-staging/)
- [Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials](https://scholariq.org/papers/increasing-the-dose-intensity-of-chemotherapy-by-more-frequent-administration-or/)
- [Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD study](https://scholariq.org/papers/feasibility-of-a-prospective-randomised-open-label-international-multicentre/)
- [Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials](https://scholariq.org/papers/trastuzumab-for-early-stage-her2-positive-breast-cancer-a-meta-analysis-of-13/)
- [Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)](https://scholariq.org/papers/use-of-70-gene-signature-to-predict-prognosis-of-patients-with-node-negative/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Breast Lesions and Carcinomas](https://scholariq.org/topics/breast-lesions-and-carcinomas/)
- [Breast Implant and Reconstruction](https://scholariq.org/topics/breast-implant-and-reconstruction/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [Global Cancer Incidence and Screening](https://scholariq.org/topics/global-cancer-incidence-and-screening/)

## Researcher university

- [The Netherlands Cancer Institute](https://scholariq.org/institutions/the-netherlands-cancer-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.